JP2019514945A5 - - Google Patents

Download PDF

Info

Publication number
JP2019514945A5
JP2019514945A5 JP2018557398A JP2018557398A JP2019514945A5 JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5 JP 2018557398 A JP2018557398 A JP 2018557398A JP 2018557398 A JP2018557398 A JP 2018557398A JP 2019514945 A5 JP2019514945 A5 JP 2019514945A5
Authority
JP
Japan
Prior art keywords
formula
compound
general formula
acute
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018557398A
Other languages
English (en)
Japanese (ja)
Other versions
JP6932140B2 (ja
JP2019514945A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2017/060356 external-priority patent/WO2017191102A1/en
Publication of JP2019514945A publication Critical patent/JP2019514945A/ja
Publication of JP2019514945A5 publication Critical patent/JP2019514945A5/ja
Application granted granted Critical
Publication of JP6932140B2 publication Critical patent/JP6932140B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018557398A 2016-05-03 2017-05-02 アミド置換ピリジニルトリアゾール誘導体およびその用途 Expired - Fee Related JP6932140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16168165 2016-05-03
EP16168165.5 2016-05-03
PCT/EP2017/060356 WO2017191102A1 (en) 2016-05-03 2017-05-02 Amide-substituted pyridinyltriazole derivatives and uses thereof

Publications (3)

Publication Number Publication Date
JP2019514945A JP2019514945A (ja) 2019-06-06
JP2019514945A5 true JP2019514945A5 (cg-RX-API-DMAC7.html) 2020-06-11
JP6932140B2 JP6932140B2 (ja) 2021-09-08

Family

ID=55910850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018557398A Expired - Fee Related JP6932140B2 (ja) 2016-05-03 2017-05-02 アミド置換ピリジニルトリアゾール誘導体およびその用途

Country Status (42)

Country Link
US (4) US9988367B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452463B1 (cg-RX-API-DMAC7.html)
JP (1) JP6932140B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190003655A (cg-RX-API-DMAC7.html)
CN (2) CN109415347B (cg-RX-API-DMAC7.html)
AR (1) AR108262A1 (cg-RX-API-DMAC7.html)
AU (1) AU2017259870B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072542A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022749A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003105A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018011933A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180522A (cg-RX-API-DMAC7.html)
CU (1) CU24567B1 (cg-RX-API-DMAC7.html)
CY (1) CY1124084T1 (cg-RX-API-DMAC7.html)
DK (1) DK3452463T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2018000240A (cg-RX-API-DMAC7.html)
EA (1) EA035596B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP18081881A (cg-RX-API-DMAC7.html)
ES (1) ES2866109T3 (cg-RX-API-DMAC7.html)
GE (2) GEP20207158B (cg-RX-API-DMAC7.html)
HR (1) HRP20210648T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053908T2 (cg-RX-API-DMAC7.html)
IL (1) IL262557B (cg-RX-API-DMAC7.html)
JO (1) JOP20170105B1 (cg-RX-API-DMAC7.html)
LT (1) LT3452463T (cg-RX-API-DMAC7.html)
MA (1) MA44851B1 (cg-RX-API-DMAC7.html)
MX (1) MX381787B (cg-RX-API-DMAC7.html)
NI (1) NI201800115A (cg-RX-API-DMAC7.html)
PE (1) PE20190116A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018502268A1 (cg-RX-API-DMAC7.html)
PL (1) PL3452463T3 (cg-RX-API-DMAC7.html)
PT (1) PT3452463T (cg-RX-API-DMAC7.html)
RS (1) RS61771B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201809752VA (cg-RX-API-DMAC7.html)
SI (1) SI3452463T1 (cg-RX-API-DMAC7.html)
SV (1) SV2018005771A (cg-RX-API-DMAC7.html)
TN (1) TN2018000368A1 (cg-RX-API-DMAC7.html)
TW (1) TWI772295B (cg-RX-API-DMAC7.html)
UA (1) UA123791C2 (cg-RX-API-DMAC7.html)
UY (1) UY37220A (cg-RX-API-DMAC7.html)
WO (1) WO2017191102A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201808131B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
PL3458443T3 (pl) 2016-05-03 2021-03-08 Bayer Pharma Aktiengesellschaft Aromatyczne pochodne sulfonamidowe
JOP20170103A1 (ar) * 2016-05-03 2017-11-03 Bayer Pharma AG عملية لتحضير مشتقات 1-فنيل-1، 2، 4-تريازول مستبدلة بـ 5-هيدروكسي ألكيل
US10893352B2 (en) * 2016-08-24 2021-01-12 Matthew Hawkes Programmable interactive stereo headphones with tap functionality and network connectivity
US10954197B2 (en) * 2017-03-08 2021-03-23 Yogee's Bioinnovations Private Limited Cathepsin-D and angiogenesis inhibitors and compositions thereof for treating breast cancer
AU2018313853A1 (en) 2017-08-08 2020-01-02 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease
US20210253557A1 (en) 2017-10-24 2021-08-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
EP3700900A1 (en) 2017-10-24 2020-09-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
PT3700913T (pt) 2017-10-24 2022-01-31 Bayer Pharma AG Profármacos de derivados de triazol substituído e utilizações dos mesmos
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
US11020351B2 (en) * 2018-03-26 2021-06-01 Hetero Labs Limited Stable bilayer tablet compositions
US20210016350A1 (en) * 2018-04-10 2021-01-21 Hewlett-Packard Development Company, L.P. Preheat dyed build materials with preheating sources
WO2021132010A1 (ja) * 2019-12-24 2021-07-01 東京エレクトロン株式会社 成膜方法及び成膜システム
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
WO2024118667A1 (en) * 2022-11-29 2024-06-06 The United States Government As Represented By The Department Of Veterans Affairs Eif4a1 inhibitors with antitumor activity
WO2026035773A1 (en) * 2024-08-06 2026-02-12 Retex Pharmaceuticals, Inc. Vasopressin receptor 2 modulators and methods of use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042466A1 (de) 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5468448A (en) 1989-12-28 1995-11-21 Ciba-Geigy Corporation Peroxide disinfection method and devices therefor
DE4107857A1 (de) 1991-03-12 1992-09-17 Thomae Gmbh Dr K Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CA2109524A1 (en) 1991-05-10 1992-11-11 Prasun K. Chakravarty Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5326776A (en) 1992-03-02 1994-07-05 Abbott Laboratories Angiotensin II receptor antagonists
SK94393A3 (en) 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6844005B2 (en) 2002-02-25 2005-01-18 Trutek Corp Electrostatically charged nasal application product with increased strength
FR2708608B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
US5897858A (en) 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
US20010020100A1 (en) 1994-06-14 2001-09-06 G.D. Searle & Co. N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
EA003095B1 (ru) 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Антагонисты рецепторов интегринов
DE19816882A1 (de) 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Triazolone mit neuroprotektiver Wirkung
JP2002521373A (ja) 1998-07-24 2002-07-16 バイエル アクチェンゲゼルシャフト 置換されたベンゾイルシクロヘキサンジオン類
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19914140A1 (de) 1999-03-27 2000-09-28 Bayer Ag Substituierte Benzoylpyrazole
PL350884A1 (en) 1999-04-01 2003-02-10 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
DE19920791A1 (de) 1999-05-06 2000-11-09 Bayer Ag Substituierte Benzoylisoxazole
DE19921424A1 (de) 1999-05-08 2000-11-09 Bayer Ag Substituierte Benzoylketone
DE19929348A1 (de) 1999-06-26 2000-12-28 Bayer Ag Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten
US6531142B1 (en) 1999-08-18 2003-03-11 The Procter & Gamble Company Stable, electrostatically sprayable topical compositions
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR027575A1 (es) 2000-03-06 2003-04-02 Bayer Ag Benzoilciclohexenonas substituidas
US7080644B2 (en) 2000-06-28 2006-07-25 Microdose Technologies, Inc. Packaging and delivery of pharmaceuticals and drugs
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
WO2002066447A1 (en) 2001-02-21 2002-08-29 Ono Pharmaceutical Co., Ltd. 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1606264B1 (en) 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
CA2571907A1 (en) 2003-06-27 2005-01-27 Berglin Corporation Of Washington Machine for precision low stress coring and slicing of apples and other soft-cored or pitted fruits
EA010132B1 (ru) 2003-12-22 2008-06-30 Пфайзер Инк. Производные триазола в качестве антагонистов вазопрессина
US20080139560A1 (en) 2004-03-08 2008-06-12 Scion Pharmaceuticals, Inc. Ion Channel Modulators
WO2005086836A2 (en) 2004-03-08 2005-09-22 Wyeth Ion channel modulators
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
EP1824831A2 (en) 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2006117657A1 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
DE102006024024A1 (de) 2006-05-23 2007-11-29 Bayer Healthcare Aktiengesellschaft Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung
DE102008060967A1 (de) 2008-12-06 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylsulfonyltriazolone und ihre Verwendung
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
DE102009013642A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylalaninderivate und deren Verwendung
DE102009028929A1 (de) 2009-08-27 2011-07-07 Bayer Schering Pharma Aktiengesellschaft, 13353 Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
UA109650C2 (xx) * 2010-02-27 2015-09-25 Біс-арилзв'язані арилтриазолони та їх застосування
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
PL2623499T3 (pl) * 2010-10-01 2015-09-30 Taisho Pharmaceutical Co Ltd Pochodne 1,2,4-triazolonu
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2013138860A1 (en) 2012-03-22 2013-09-26 Biota Europe Limited Antibacterial compounds
SI3215498T1 (sl) 2014-11-03 2018-11-30 Bayer Pharma Aktiengesellschaft Hidroksialkil-substituirani derivati feniltriazola in njihove uporabe
WO2017191115A1 (en) * 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
JOP20170103A1 (ar) * 2016-05-03 2017-11-03 Bayer Pharma AG عملية لتحضير مشتقات 1-فنيل-1، 2، 4-تريازول مستبدلة بـ 5-هيدروكسي ألكيل
US9988367B2 (en) * 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof

Similar Documents

Publication Publication Date Title
JP2019514945A5 (cg-RX-API-DMAC7.html)
HRP20210648T1 (hr) Amid-supstituirani derivati piridiniltriazola i njihova uporaba
TW544453B (en) Novel guanidine mimics as factor Xa inhibitors
DE3750687T2 (de) Angiotensin II-Rezeptorblockierende Imidazole.
JP4680903B2 (ja) ピリダジニル−ピペラジンおよびそれらのヒスタミンh3受容体リガンドとしての使用
JP4463317B2 (ja) 置換イミダゾールおよび殺虫剤としてのその使用
SA517381429B1 (ar) مشتقات فينيل تريازول مستبدلة مع هيدروكسي ألكيل واستخداماتها
AU2014272776C1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
AU2010200135A1 (en) Novel aryl-and heteroarylpiperazines
JP2010515715A5 (cg-RX-API-DMAC7.html)
JP2006504658A5 (cg-RX-API-DMAC7.html)
CA2262252C (en) Method of treating heart failure
KR20130004316A (ko) 비스아릴-결합된 아릴트리아졸론 및 그의 용도
JP2000514088A (ja) グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール
JP2010507602A5 (cg-RX-API-DMAC7.html)
JP2002080453A (ja) 選択的シクロオキシゲナーゼ−2阻害物質となる置換ピリジン
CN106304835A (zh) sGC刺激剂
JP2002520274A (ja) バルサルタンとカルシウムチャンネルブロッカーの抗高血圧組合わせ
JP2003513961A (ja) シクロオキシゲナーゼ−2の阻害剤である5−アリール−1h−1,2,4−トリアゾール化合物とそれを含む医薬品組成物
CZ280018B6 (cs) 4-alkylimidazolové deriváty
JP2014532726A5 (cg-RX-API-DMAC7.html)
JP2023552583A5 (cg-RX-API-DMAC7.html)
WO2017013010A1 (de) Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
JP2012509858A (ja) 肥大性心筋症治療用のホスホジエステラーゼタイプIII(PDEIII)インヒビターまたはCa2+感作剤
JP2012503005A5 (cg-RX-API-DMAC7.html)